Literature DB >> 23813935

Antiviral cell therapy: is this the future?

Juan C Gea-Banacloche1.   

Abstract

Mesh：

Year:  2013        PMID： 23813935      PMCID： PMC3695358          DOI： 10.1182/blood-2013-05-500082

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Authors:  Ann M Leen; G Doug Myers; Uluhan Sili; M Helen Huls; Heidi Weiss; Kathryn S Leung; George Carrum; Robert A Krance; Chung-Che Chang; Jeffrey J Molldrem; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

2.  Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease.

Authors:  Waseem Qasim; Sophie Derniame; Kimberly Gilmour; Robert Chiesa; Martin Weber; Stuart Adams; Kanchan Rao; Persis Amrolia; Nicholas Goulden; Paul Veys; Hubert Gaspar
Journal:  Br J Haematol       Date:  2011-04-19       Impact factor: 6.998

3.  Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.

Authors:  Emily Blyth; Leighton Clancy; Renee Simms; Chun K K Ma; Jane Burgess; Shivashni Deo; Karen Byth; Ming-Celine Dubosq; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood       Date:  2013-02-22       Impact factor: 22.113

4.  Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.

Authors:  Michael Uhlin; Jens Gertow; Mehmet Uzunel; Mantas Okas; Sofia Berglund; Emma Watz; Mats Brune; Per Ljungman; Mark Maeurer; Jonas Mattsson
Journal:  Clin Infect Dis       Date:  2012-07-17       Impact factor: 9.079

5.  Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Authors:  Kenneth P Micklethwaite; Barbara Savoldo; Patrick J Hanley; Ann M Leen; Gail J Demmler-Harrison; Laurence J N Cooper; Hao Liu; Adrian P Gee; Elizabeth J Shpall; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

6.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

Authors:  J Joseph Melenhorst; Ann M Leen; Catherine M Bollard; Máire F Quigley; David A Price; Cliona M Rooney; Malcolm K Brenner; A John Barrett; Helen E Heslop
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

7.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

8.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Authors:  Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

9.  Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Authors:  Ulrike Gerdemann; Jacqueline M Keirnan; Usha L Katari; Ryu Yanagisawa; Anne S Christin; Leslie E Huye; Serena K Perna; Sravya Ennamuri; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2012-07-17       Impact factor: 11.454

10.  Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.

Authors:  Cliona Rooney; Ann Leen
Journal:  Mol Ther Nucleic Acids       Date:  2012-11-13       Impact factor: 10.183
  10 in total
  1 in total

1.  Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Authors:  M Ramanathan; P Teira; M Battiwalla; J Barrett; K W Ahn; M Chen; J Green; M Laughlin; H M Lazarus; D Marks; A Saad; M Seftel; W Saber; B Savani; E K Waller; J Wingard; J J Auletta; C A Lindemans; M Boeckh; M L Riches
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.